Mr. Jacek Antas reports

HELIX BIOPHARMA CORP. APPOINTS JAMES B. MURPHY AS CHIEF FINANCIAL OFFICER

Helix BioPharma Corp. has appointed James B. Murphy as chief financial officer (CFO) of the company.

Mr. Murphy is a certified public accountant with over 30 years of experience in finance and operations management. He is currently a consultant with Danforth Advisors LLC, a leading provider of outsourced strategic and operational specialists across functions in the life sciences industry. While at Danforth, Mr. Murphy has served over 15 private and publicly held life sciences companies as CFO and CFO Advisor, helping them secure over $500-million (U.S.) in financing and successfully execute pivotal asset transactions. Mr. Murphy will function as a consultant to Helix pursuant to a consulting agreement between the company and Danforth.

Jacek Antas, chief executive officer of Helix, said: "We are thrilled to welcome Jim to Helix. His extensive experience in guiding life sciences companies through key financial milestones, coupled with his proven ability to drive strategic growth, makes him an invaluable addition to our team as we remain laser focused on advancing our CEACAM6 platform and new assets to get them to patients as soon as possible."

"The Helix team and its technology has a tremendous amount of potential. Helix is well-positioned to make a significant impact in oncology and I look forward to contributing to its financial and operational success. I welcome the opportunity to work with Helix management and its board of directors to continue the promise of Helix," said Mr. Murphy.

About Helix BioPharma Corp.

Helix BioPharma is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on the company's proprietary technological platform DOS47. Helix is listed on the Toronto Stock Exchange under the symbol HBP, on OTC Pink under the symbol HBPCD and on FWB under the symbol HBP0.

We seek Safe Harbor.